Johnson & Johnson

- No indication of new fundraising through debt or equity in the near term. - The Kenvue separation generated significant cash and value, including proceeds from debt offering and IPO, reducing Johnson & Johnson’s shares by approximately 191 million (7%). - Johnson & Johnson retained around 180 million shares of Kenvue stock for potential future cash proceeds. - Strong free cash flow generation (~$12 billion YTD through Q3 2023) supports capital allocation priorities. - The company plans to use its robust cash flow and strong credit profile for business development, dividends, and share repurchases. - Ended Q3 2023 with approximately $24 billion in cash and marketable securities, $30 billion in debt (net debt ~$6 billion). - No mention of plans for immediate new debt or equity fundraising; focus is on disciplined capital allocation using existing resources.

- Johnson & Johnson is progressively adding manufacturing capacity for Carvykti: - Expanded original launch site in New Jersey. - New manufacturing site operational in Belgium, Europe. - Utilized excess capacity from Novartis to bolster supply. - Significant scaling of lentivirus component production at Switzerland factory. - Building a new lentivirus factory in the Netherlands, expected ready in 2024. - MedTech segment implementing a restructuring program aimed at simplifying operations: - Focus on Orthopedics with plans to exit certain markets and product lines. - Approximately $250 million revenue reduction expected over two years. - Program completion expected by end of 2025. - Goal to improve future margin profile, accelerate growth, and enhance profitability. - Continuing to invest in pipeline programs with multiple ongoing and planned clinical trials and data presentations in Innovative Medicines. - Strong cash position ($24B) and strategic disciplined capital allocation including business development, dividends, and share repurchases.

- MedTech procedural growth expected at 5% to 7% overall in 2024, maintaining elevated market levels seen in 2023. - Continued robust procedural increases projected across MedTech segments beyond bariatrics. - Immunology business, particularly Tremfya, anticipated to achieve significant growth with upcoming approvals in ulcerative colitis and Crohn's disease. - Carvykti showing strong demand with ongoing capacity expansions; commercial momentum expected to continue into 2024. - Pharma sales growth supported by key assets like Tremfya, Erleada, Uptravi, Darzalex, and new product launches (Tecvayli, Talvey). - Pipeline developments (e.g., MARIPOSA chemo-free regimen, nipocalimab) add to future revenue growth potential. - China remains a key growth driver despite price headwinds from value-based procurement. - Overall, company expects healthy top-line growth and margin improvements into 2024 and beyond.

- Johnson & Johnson raised full-year 2023 operational sales growth guidance to 8.5%-9%, with adjusted earnings per share (EPS) guidance of $10.02 to $10.08, representing 12.5% growth at midpoint. - For 2024, management expects continued healthy top-line growth with operational sales growth in Innovative Medicines and MedTech. - Adjusted pre-tax operating margin for 2023 is expected to improve by approximately 50 basis points. - Full benefit of approximately 191 million net share reduction from Kenvue separation to be reflected in 2024 financials, supporting EPS growth. - 2024 margins expected to be similar to 2023 levels; no specific margin guidance yet. - Pipeline innovations, new product launches (e.g., Carvykti, Tecvayli), and regulatory approvals to support future growth. - Stelara biosimilars not expected in the U.S. in 2024, aiding sales stability. - Long-term confidence in hitting $57 billion pharma sales target by 2025, fueled by key assets and pipeline progress.

The transcript does not provide specific numerical data or details on current or expected orderbook or pending orders for Johnson & Johnson. However, relevant insights include: - Strong demand and increasing capacity for Carvykti, with ongoing ramp-up in manufacturing sites (New Jersey, Belgium, Switzerland, and the Netherlands). - Continued growth momentum expected in 2023 and into 2024 across key portfolios including Immunology, MedTech, and Innovative Medicines. - Robotic-assisted surgery (Ottava) is in early adoption stages with single-digit penetration; significant growth potential anticipated. - MedTech procedural growth expected at 5-7% in 2024, aligned with overall market growth. - Immunology portfolio showed strong 12.4% growth in the recent quarter despite biosimilar competition. - New product launches and pipeline readouts (e.g., MARIPOSA, Tremfya) poised to drive future growth. No explicit mention of quantitative orderbook or pending orders was made.